PMID- 36249041
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - The risk factors and early predictive model of hematotoxicity after CD19 chimeric 
      antigen receptor T cell therapy.
PG  - 987965
LID - 10.3389/fonc.2022.987965 [doi]
LID - 987965
AB  - Hematotoxicity is the most common long-term adverse event after chimeric antigen 
      receptor T cell (CAR-T) therapy. Here, a total of 71 patients with relapsed or 
      refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) or large B-cell 
      lymphoma (LBCL) were used to develop an early hematotoxicity predictive model and 
      verify the accuracy of this model. The incidences of early hematotoxicity at 3 
      month following CAR-T infusion in B-ALL and LBCL were 45.5% and 38.5%, 
      respectively. Multivariate analyses revealed that the severity of cytokine 
      release syndrome (CRS) was an independent risk factor affecting early 
      hematotoxicity. The analysis between the peak cytokine levels and early 
      hematotoxicity suggested that tumor necrosis factor-alpha (TNF-alpha) and C-reactive 
      protein (CRP) were closely associated with early hematotoxicity. Then, an early 
      predictive model of hematotoxicity was constructed based on the peak contents of 
      TNF-alpha and CRP. This model could diagnose early hematotoxicity with positive 
      predictive values of 87.7% and 85.0% in training and validation cohorts, 
      respectively. Lastly, we constructed the nomogram for clinical practice to 
      predict the risk of early hematotoxicity, which performed well compared with the 
      observed probability. This early predictive model is instrumental in the risk 
      stratification of CAR-T recipients with hematotoxicity and early intervention for 
      high-risk patients.
CI  - Copyright (c) 2022 Wang, Song, Geng, Gao, Xu, Tang, Ni, Chen, Chen, Wang, Fu, Feng, 
      Yu, Wang and Yang.
FAU - Wang, Yang
AU  - Wang Y
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Song, Zhiqiang
AU  - Song Z
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Geng, Yuke
AU  - Geng Y
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Gao, Lei
AU  - Gao L
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Xu, Lili
AU  - Xu L
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Tang, Gusheng
AU  - Tang G
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Ni, Xiong
AU  - Ni X
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Chen, Li
AU  - Chen L
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Fu, Weijia
AU  - Fu W
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Feng, Dongge
AU  - Feng D
AD  - HuaDao Biopharma (Shanghai) Limited Corporation, Shanghai, China.
FAU - Yu, Xuejun
AU  - Yu X
AD  - HuaDao Biopharma (Shanghai) Limited Corporation, Shanghai, China.
FAU - Wang, Libing
AU  - Wang L
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Yang, Jianmin
AU  - Yang J
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220930
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9561932
OTO - NOTNLM
OT  - acute lymphoblastic leukemia
OT  - chimeric antigen receptor T cell
OT  - early predictive model
OT  - hematotoxicity
OT  - large B-cell lymphoma
OT  - risk factors
COIS- Authors DF and XY are employed by HuaDao Biopharma (Shanghai) Limited 
      Corporation, a biotechnology company focusing on the research and development of 
      cellular immunotherapy. The remaining authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/01/01
CRDT- 2022/10/17 05:17
PHST- 2022/07/06 00:00 [received]
PHST- 2022/09/20 00:00 [accepted]
PHST- 2022/10/17 05:17 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.987965 [doi]
PST - epublish
SO  - Front Oncol. 2022 Sep 30;12:987965. doi: 10.3389/fonc.2022.987965. eCollection 
      2022.